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Estrogen induces glomerulosclerosis in analbuminemic rats. Progres-
sion of chronic renal disease is usually more rapid in males, both in
humans and in experimental animals. Estrogen-replacement studies indi-
cate that this may be related to the beneficial effects of estrogen on the
lipoprotein profile. However, in hyperlipidemic analbuminemic rats
(NAR), females are more prone to develop renal injury than males, and
ovariectomy tends to decrease triglyceride levels and prevent renal
disease. Therefore, we studied the effects of estrogen administration on
lipoproteins, and the induction of renal injury in uninephrectomized
female and male NAR. Ovariectomized and orchidectomized uninephrec-
tomized NAR were treated with estradiol implants for 24 weeks. In an
additional group of ovariectomized rats, the implant was removed after 12
weeks. Both in ovariectomized and orchidectomized NAR, estradiol
caused severe hypercholesterolemia (9 to 12 mmol/liter) and hypertriglyc-
eridemia (6 to 8 mmol/liter) after six weeks. Subsequently, these rats
developed severe proteinuria, reaching 209 6 25 and 95 6 43 mg/day,
respectively, after 24 weeks. At this point there was severe glomerular
sclerosis, with a respective score of 107 6 21 and 61 6 33. In terminal
blood samples the most pronounced increase in lipid levels were observed
in very low density lipoproteins (VLDL), intermediate density lipoproteins
(IDL) and low density lipoproteins (LDL). In contrast, ovariectomized
NAR and orchidectomized NAR without exogenous estrogen had much
lower lipid levels (cholesterol 5 to 7 mmol/liter and triglycerides 1 to 2
mmol/liter) after six weeks. These rats, or ovariectomized NAR where the
estrogen treatment had been withdrawn, had practically no proteinuria
(4 6 1, 19 6 11, and 13 6 4 mg/day, respectively) or renal damage
(glomerulosclerosis score 1 6 0.4, 5 6 3 and 3 6 1, respectively) after 24
weeks. Thus, in hypertriglyceridemic analbuminemic rats, estrogen-treat-
ment causes further increases in both triglycerides and cholesterol. Most
probably these changes contribute to the development of renal injury by
estrogen in this model. This effect of estrogen, which has also been
observed in the Zucker rat, is unique for the hypertriglyceridemic state
and deserves further study.
Gender affects the rate of progression of chronic renal disease
in humans, where progression is usually more rapid in men [1].
This has also been observed in experimental studies in rats [2–4].
Classical risk factors for the progression of renal disease are
glomerular hypertension and hypertrophy. However, it has not
been possible to relate gender effects to differences in glomerular
capillary pressure [2, 4]. The development of proteinuria and
glomerular hypertrophy are more pronounced in male than in
female rats [2, 4–6]. Both proteinuria and glomerular hypertro-
phy are prevented by castration [7, 8]. Nevertheless, even in the
absence of proteinuria, castrated male rats still demonstrate some
glomerular hypertrophy [2]. Other risk factors involved in the
progression of renal disease must therefore be sensitive to gender.
Hyperlipidemia, recognized as contributing to atherosclerosis,
is also emerging as a risk factor for progression of renal disease [9,
10]. Estrogen replacement has beneficial effects on lipoprotein
profile in relation to atherosclerotic risk in postmenopausal
women [11, 12], while ovariectomy increases the incidence of
coronary disease in premenopausal women [13]. In hypercholes-
terolemic Imai rats, ovariectomy has been shown to have an
aggravating effect on renal injury in females [8, 14], while estrogen
attenuates glomerular injury in males [15]. These effects in Imai
rats may be related to changes in lipid metabolism because
ovariectomy increased plasma cholesterol levels [14] and estrogen
caused a reduction in plasma cholesterol [15]. However, in
normolipidemic Munich-Wistar rats ovariectomy had no delete-
rious effect on renal function [2]. Previously we observed that
ovariectomy decreased plasma triglyceride levels [16] and pre-
vented renal disease in aging [17] and uninephrectomized [18]
female analbuminemic rats (NAR). In ovariectomized obese
Zucker rats estrogen administration induces severe hypertriglyc-
eridemia and rapid progression of renal injury [19]. Thus, depend-
ing on the metabolic status, estrogen may have variable and even
opposite effects on the progression of renal disease. To further
probe this issue we presently studied the effects of estrogen
administration on lipoproteins, glomerular hypertrophy and the
induction of renal injury in uninephrectomized female and male
NAR.
METHODS
Nine-week-old female NAR rats (N 5 23) weighing 150 to
175 g, and male NAR (N 5 12), weighing 200 to 250 g were
obtained from our own pathogen-free colony (which was founded
with animals generously donated by Dr. S. Nagase, Tokyo, Japan).
All these rats underwent right nephrectomy (UNX), all female
rats were bilaterally ovariectomized (OVX), and all male rats
were orchidectomized (ORCH) under hypnorm-diazepam anes-
thesia and sterile conditions. Simultaneously 19 of these rats (13
females and 6 males) were treated with a subcutaneous silastic
implant containing about 1 mg of 17b-estradiol (E2). The rats
were studied for a period of 24 weeks. In 4 females the E2 implant
was removed after 12 weeks. The OVX females (N 5 10) and
ORCH males (N 5 6) were used as controls. For the sake of
comparison terminal data collected 22 weeks after uninephrec-
tomy from an additional cohort of NAR (10 females and 8 males),
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that were neither ovariectomized nor orchidectomized, are also
presented.
Renal function, plasma lipids and protein
Urine was collected every six weeks until 24 weeks after UNX
for determination of urinary protein excretion. The rats were
weighed and placed in macrolon metabolism cages, with free
access to food and water. Two consecutive 24 hours urine samples
were collected. At 6 and 12 weeks the animals were also anesthe-
tized with Na-pentobarbital (60 mg/kg), and 1 ml of blood was
sampled in heparinized tubes by puncture of the tail artery with a
needle (25G) for determination of plasma cholesterol, triglycer-
ides, protein and creatinine. Besides plasma lipids, creatinine and
protein, terminal blood samples at 24 weeks post-UNX were also
used for determination of plasma lipoproteins. Tail cuff pressure
was measured in conscious animals in the 24th week (IITC, San
Diego, CA, USA).
Tissue processing
At the end of the experiment after 25 weeks (when the rats were
about 34 weeks old) the animals were exsanguinated in the fed
state by puncture of the abdominal aorta under pentobarbital
anesthesia. Subsequently the left kidney was perfused for one
minute at a pressure of 100 mm Hg with heparinized (5 IU/ml)
phosphate-buffered saline, pH 7.4 (PBS), containing 6% sucrose.
After sampling the cranial apex for lipid histochemistry, the
remaining tissue was perfused for an additional two minutes with
0.025% glutaraldehyde and 2% paraformaldehyde in 0.1 M phos-
phate buffer. The sample for lipid histochemistry was quickly
frozen in liquid nitrogen. Coronal tissue slices of 1 mm thickness
were cut from the midportion of the kidney, fixed in 2% parafor-
maldehyde in phosphate buffered saline (PBS) at 4°C for three
hours and processed for glycol methacrylate embedding as de-
scribed previously [20]. Kidneys of rats that died before the end of
the experiment were fixed in 2% paraformaldehyde in PBS.
Staining procedures for light microscopy
For the immunohistochemical localization of macrophages
plastic sections were processed as described [20]. In short, sections
were dried at 37°C for two hours, pretreated with 0.01% trypsin
for five minutes at 37°C and incubated in an appropriate dilution
of mouse anti-rat macrophage antibody (ED1; kindly provided by
Dr. C. Dijkstra, Free University, Amsterdam, The Netherlands)
for two hours at 37°C. Endogenous peroxidase was blocked in
PBS, containing 0.06% H2O2 for 30 minutes at room temperature.
A peroxidase-conjugated rabbit anti-mouse antibody (Dakopatts,
Glostrup, Denmark) was applied for one hour in a dilution of 1 to
20 in PBS, containing 5% normal rat serum. Peroxidase activity
was developed using DAB and H2O2 for 12 minutes. Sections
were counterstained with PAS and Mayers hematoxylin. To
improve morphological detail, sections were covered with two
drops of complete Technovit 8100 medium (Solution A1B, 30:1)
as used for embedding.
Lipid histochemistry
Glomerular lipid deposits were scored in 4 mm frozen sections
stained by the Oil Red O method. Oil Red O stained sections
were scored semiquantitatively on a scale of 0 to 41 [20]. Briefly,
if 25% of the glomerulus was affected, a score of 11 was
adjudged, 50% was scored as 21, 75% as 31 and 100% as 41.
The ultimate score is then obtained by multiplying the degree of
change by the percentage of glomeruli with the same degree of
injury and additions of these scores. A total number of 50
glomeruli per animal was scored moving from cortex to medulla.
Glomerular diameter and sclerosis
Glomerular diameter was measured in PAS stained sections as
described previously [20]. At least 50 glomerular profiles (Bow-
man’s capsule) per kidney were traced. Glomerulosclerosis lesions
were defined by the presence of focal and segmental glomerular
scarring and obliteration of glomerular capillaries with increased
mesangial cellularity, mesangial matrix expansion and adhesion
formation between the tuft and Bowman’s capsule. The severity of
glomerulosclerosis was scored semiquantitatively on a scale of 0 to
41 [21] in PAS-stained sections. Fifty glomeruli were scored per
animal with the same system that was used to assess lipid
deposition.
Lipoprotein isolation by density-gradient ultracentrifugation
In non-fasting rats plasma lipoproteins were separated by
density-gradient ultracentrifugation [22] into six fractions [chylo-
microns and very low density lipoproteins (VLDL), d , 1.006
g/ml; intermediate density lipoprotein (IDL), d 1.006 to 1.019
g/ml; low density lipoproteins (LDL), LDL1, d 1.019 to 1.04 g/ml,
and LDL2, 1.04 to 1.063 g/ml; and high density lipoprotein
(HDL), d 1.063 to 1.21 g/ml). The subdivision of LDL into LDL1
and LDL2 was performed to separate the apo B containing
lipoproteins from the other particles present in the total LDL
density range of 1.019 to 1.063 g/ml [23]. Lipoprotein cholesterol
and triglycerides were measured as described below.
Biochemical analyses
Plasma and urinary protein was determined by the Bradford
method. Plasma and urinary creatinine was determined colori-
metrically (Sigma, St. Louis, MO, USA). Enzymatic methods were
used for the determination of total plasma cholesterol and
triglycerides (Boehringer GmbH, Mannheim, Germany). E2 con-
centrations in plasma were determined using the 17b-125I-Estra-
diol radioimmunoassay (ICN Biochemicals Inc., Costa Mesa, CA,
USA), according to the manufacturer’s specifications, following a
standard extraction procedure on C18 columns (3 ml, 200 mg).
The sensitivity of the E2 assay was 13.5 pg/ml, and intra- and
interassay coefficients of variation were 15% and 9%, respectively.
Calculations and statistical analysis
Plasma triglycerides, proteinuria, glomerular injury score and
lipid deposition were log-normalized to achieve a normal distri-
bution. Results are expressed as arithmetic means 6 standard
errors (SEM). Serial data were tested by two-way analysis of
variance and terminal data by one-way analysis of variance.
Student-Neuman-Keuls test for multiple comparisons was applied
if the variance ratio (F) reached statistical significance (P , 0.05).
RESULTS
In both OVX and ORCH NAR the E2 caused marked hyper-
triglyceridemia as well as hypercholesterolemia followed by rapid
development of proteinuria, glomerular lipid deposition and
glomerulosclerosis. Removing the E2 implant caused reduction of
hyperlipidemia, a fall in proteinuria and prevented glomerular
lesions.
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Three of the OVX1E2 NAR died in the last month of the
experiment. Their kidneys were harvested for morphological
examination. Thus, terminal blood and urine samples were only
collected in six rats in this group. Body weight increased markedly
over the 24 week experiment in OVX female and ORCH male
NAR (terminal values were 389 6 11 and 428 6 11 g, respective-
ly), whereas the body wt only increased slightly in the OVX1E2
and ORCH1E2 NAR (reaching 199 6 8 and 260 6 7 g,
respectively). Terminal body wt was intermediate in the OVX1E2
NAR where the E2 implant had been removed after 12 weeks
(335 6 8 g). Plasma E2 concentration in the OVX and ORCH
MAR were close to the detection limit of the assay, and were
more than threefold increased in the E2-supplemented rats
(Table 1). The E2 levels were not different in the OVX1E2 and
ORCH1E2 NAR. Tail-cuff pressure was similar in OVX (134 6
6 mm Hg) and OVX1E2 (146 6 17 mm Hg) NAR and slightly
lower in ORCH1E2 (133 6 5 mm Hg) than in ORCH NAR
(165 6 6 mm Hg; P , 0.05).
Chronic E2 treatment induced marked increments in choles-
terol and triglyceride levels. At six weeks post-UNX when all the
rats were still free of proteinuria, cholesterol levels in E2 treated
rats were between 10 and 12 mmol/liter as compared to values of
about 5 mmol/liter in the non-E2 treated NAR (Fig. 1A). There
were slight gender-related diferences, the cholesterol levels being
higher in the females than in the males, both with and without the
E2 treatment. Triglycerides were about 7 mmol/liter in E2-treated
NAR as compared to about 1 to 2 mmol/liter in non-E2 treated
castrated NAR at six weeks post-UNX, when all the rats were still
free of proteinuria. These differences remained more or less
present for the rest of the experiment, although there was some
fall in triglyceride levels in the terminal samples in ORCH1E2
NAR (Fig. 1B). As a result, the terminal triglyceride levels were
slightly lower in ORCH1E2 than in OVX1E2 NAR. Removing
the E2 implant after 12 weeks in OVX1E2 NAR reduced plasma
lipid levels to intermediate levels between those found in E2-
treated and E2-non-treated OVX NAR (Fig. 1). Lipoprotein
composition in E2-treated NAR revealed a marked increase of
VLDL and IDL, particularly in the OVX1E2 NAR (Table 1).
There was a mild increase in LDL1, whereas LDL2 and HDL
were increased in ORCH1E2 NAR, but not in OVX1E2 NAR.
Proteinuria became evident at 12 weeks post-UNX in
Fig. 1. Effects of estrogen on cholesterol (A) and triglycerides (B) in
analbuminemic rats (NAR) after uninephrectomy (UNX). Symbols are:
circles, ovariectomized females with estradiol (E2) implants (F) or
without E2 (E); squares, ovariectomized females with E2 implants (f)
that were removed 12 weeks post-UNX (M); triangles, males with E2
implants () or orchidectomized males without E2 (). *P , 0.01 versus
ovariectomized or orchidectomized where applicable.
Table 1. Effects of estrogen on plasma estradiol (E2), cholesterol (CH), triglycerides (TG) and lipoproteins in uninephrectomized orchidectomized










E2 pg/ml 13.5 6 3.5 50.9 6 9.7a 13.4 6 1.6 47.8 6 15.6b
CH mM 7.5 6 0.4 16.0 6 0.9aa 6.3 6 0.7 12.1 6 1.2bbc
TG mM 2.7 6 0.3 6.7 6 0.8aa 1.7 6 0.4 4.4 6 0.6bbc
VLDL CH mM 0.26 6 0.09 0.71 6 0.26a 0.04 6 0.02 0.40 6 0.20b
IDL CH mM 0.49 6 0.12 2.24 6 0.59a 0.46 6 0.05 1.03 6 0.42bc
LDL1 CH mM 2.36 6 0.16 3.63 6 0.65a 1.10 6 0.26a 2.79 6 0.32b
LDL2 CH mM 2.64 6 0.24 2.61 6 0.46 1.79 6 0.22 3.19 6 0.19b
HDL CH mM 2.29 6 0.19 1.76 6 0.53 1.17 6 0.13a 3.06 6 0.22bc
OVX NAR and ORCH NAR were treated with an estradiol (E2) implant for 24 weeks and untreated OVX NAR and ORCH NAR served as the
respective controls. Plasma estradiol (E2), cholesterol (CH), triglycerides (TG) and lipoproteins were measured in the non-fasted state at the end of
the experiment.
a P , 0.05, aa P , 0.01 vs. OVX
b P , 0.05, bb P , 0.01 vs. ORCH
c P , 0.05 vs. OVX 1 E2
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OVX1E2 NAR and at 18 weeks post-UNX in ORCH1E2 NAR,
and subsequently increased rapidly in both groups (Fig. 2). The
levels were higher in the OVX1E2 NAR than in the ORCH1E2
NAR. Urinary protein was low in ORCH NAR and even lower in
OVX NAR (terminal values listed in Table 2). In the group of
OVX1E2 rats (N 5 4) where the implant was removed at 12
weeks post-UNX, proteinuria fell from 33 6 13 mg/day to 13 6 4
mg/day at the end of the experiment. However, this value was
significantly higher than in the OVX NAR that had never been
proteinuric. Plasma creatinine in terminal blood samples was
similar in all groups (Table 2).
Glomerular diameter was higher in OVX1E2 than in OVX
NAR, but lower in ORCH1E2 than in both ORCH NAR and
OVX1E2 NAR. Glomeruli were much larger in ORCH than in
OVX NAR. Glomerular macrophages, lipid deposition and scle-
rosis (Table 2) were highest in OVX1E2 NAR, slightly lower in
ORCH1E2 NAR, and practically absent in OVX and ORCH
NAR. The OVX1E2 NAR, where the implant was removed after
12 weeks, were practically free of glomerular damage and dem-
onstrated glomerular diameters only slightly higher than those
seen in the OVX NAR.
Cholesterol and triglyceride levels were markedly higher in
female than in male NAR (Table 3). There were no differences in
systolic blood pressure and plasma creatinine. Proteinuria and
glomerular damage were evident in a number of the females, but
because of the large variation at this stage, significance was only
reached for lipid deposition. Glomerular diameters were signifi-
cantly lower in female than in male NAR.
DISCUSSION
Both in ovariectomized (OVX) and in orchidectomized
(ORCH) analbuminemic rats (NAR), exogenous estrogen caused
severe hypercholesterolemia and hypertriglyceridemia. Subse-
quently, these rats developed severe proteinuria and glomerular
lesions. In contrast, OVX NAR without endogenous estrogen,
ORCH NAR without exogenous estrogen, or OVX NAR where
the estrogen treatment had been withdrawn, had practically no
renal damage or proteinuria.
The dramatic induction of renal disease by E2 in NAR is
complementary to the protective effects of male gender and
ovariectomy that we and others have recently described in this
model [17, 18, 24, 25]. The fact that exposure to 17B-estradiol
(E2) causes a more rapid development of renal injury than do
endogenous estrogens is probably due to the fact that the plasma
levels achieved by continuous E2 treatment are in the same range
as the proestrous levels found in adult female NAR [26]. The E2
levels in cyclic female rat are highest during proestrous, which
lasts about 10% of the total ovarian cycle of five days [27]. Thus,
although the E2 levels were not out of the physiological range in
the E2-treated rats, the cumulative dose over the treatment
period was probably an order of magnitude higher than the
exposure to E2 in a cyclic female rat. The E2-treatment induced
similar plasma E2 levels in OVX and ORCH NAR; thus, the
differences in plasma lipids and the degree of renal injury between
these two groups may be genetically determined.
The present study demonstrates conclusively that androgens
play a minor role in the balance of factors affecting kidney
function in NAR, because orchidectomized males were not sus-
ceptible to renal disease as was found previously in non-castrated
male NAR [17, 25]. Moreover, for the sake of comparison, we
have included previously unpublished findings from non-castrated
male and female NAR, measured at 22 weeks after uninephrec-
tomy (Table 3). This period is similar to the period of exposure to
uninephrectomy in the present study (25 weeks). Comparing the
data in Tables 1 and 2 on the one hand, and in Table 3 on the
other hand confirms that there were practically no differences
between orchidectomized and non-castrated males in any of the
measured plasma or urine variables, and that renal pathology was
absent in both groups.
Under most circumstances estrogen offers nephroprotection
[1], or is without influence [2, 28, 29], whereas androgen has
adverse effects [4, 29]. However, in models showing spontaneous
hypertriglyceridemia the situation appears to be reversed. Estro-
gen administration causes further increases in triglyceride levels in
JCR:LA-corpulent rats [30]. Female obese Zucker rats [31] as
well as female NAR [18] demonstrate hypertriglyceridemia prior
to the development of proteinuria, and in OVX obese Zucker rats
treated with estrogen there are preliminary data demonstrating
marked exacerbation of pre-existent hypertriglyceridemia and
rapid progression of renal injury [19]. Recently, we found that
estrogen replacement in OVX rats with adriamycin-induced ne-
phrotic syndrome caused marked exacerbation of hypertriglycer-
idemia [29]. The hypertriglyceridemic effects of estrogen in these
models appears to be due to an increase in hepatic fatty acid
synthesis and triglyceride secretion [16, 30, 32]. Moreover, estro-
gen replacement in OVX nephrotic rats failed to reduce LDL
cholesterol as was observed in the control OVX rats [32]. The
effects of estrogen-replacement on LDL cholesterol was not
studied in the Zucker rats, but there was a pronounced increase in
total cholesterol [19]. In the present study, we observed that
estrogen-replacement in NAR also failed to decrease LDL-
cholesterol. In fact, both in ORCH NAR and in OVX NAR
estrogen caused marked increases of cholesterol in all lipoprotein
fractions. The mechanism of this estrogen-induced hypercholes-
terolemia is not clear. It was already present after six weeks, when
Fig. 2. Effects of estrogen on proteinuria in analbuminemic rats (NAR)
after uninephrectomy (UNX). Symbols are: circles, ovariectomized fe-
males with estradiol (E2) implants (F) or without E2 (E); squares,
ovariectomized females with E2 implants (f) that were removed 12 weeks
post-UNX (M); triangles, males with E2 implants () or orchidectomized
males without E2 (). Note that proteinuria is indicated by a log scale.
*P , 0.05 and **P , 0.01 versus ovariectomized or orchidectomized
where applicable.
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proteinuria was not yet present, and can therefore not have been
secondary to renal disease. Stimulation of apolipoprotein A-I
synthesis [33] does not appear to be a consistent effect because
HDL cholesterol was unchanged by E2-treatment in the OVX rats
where the highest cholesterol levels were present. It is possible
that the high cholesterol levels in VLDL, and consequently in IDL
and LDL1, were the result of stimulated de novo hepatic choles-
terol synthesis [34].
Hyperlipidemic effects of estrogen are unique for the hypertri-
glyceridemic state and have been observed in patients with
primary hypertriglyceridemia, where hyperestrogenism, secondary
to pregnancy [35, 36], estrogen replacement [37, 38] or contra-
ceptive agents [39, 40] can result in excessively high triglyceride
levels. No studies have been conducted in patients with the
nephrotic syndrome, but some diabetic women do appear to have
an exaggerated hypertriglyceridemic response to postmenopausal
hormone replacement [41].
The importance of estrogen-driven hyperlipidemia in the
pathogenesis of renal injury in NAR is underscored by the marked
reduction of proteinuria, glomerular macrophages and glomerular
lipid deposition observed after ovariectomy [18] or withdrawal of
estrogen when manifest proteinuria was already present (this
study). Thus, it is likely that the atherosclerotic risk profile
induced by estrogen replacement during hypoalbuminemia is
responsible for the rapid development of renal disease in the
NAR. Hypertriglyceridemia may contribute to the development
of renal disease because of avid binding of VLDL and IDL to
glomerular epithelial [42, 43] and mesangial [44, 45] cells. Hyper-
triglyceridemia has also been implicated in the pathogenesis of
renal damage in normalbuminemic models, such as the Zucker rat
[19, 31], obesity induced by hypothalamic lesions [46], and in
patients with gross obesity [47, 48] or familial dysbetalipoproteine-
mia, otherwise known as type III hyperlipidemia [49, 50]. Dietary
hypercholesterolemia is associated with high cholesterol levels in
VLDL and IDL [51, 52] and pathogenic effects in the kidney [53,
54].
The effects of estrogen on glomerular hypertrophy in these
uninephrectomized NAR were variable. In the OVX1E2 NAR,
estrogen replacement caused glomerular diameters to increase,
and this effect was partially reversed by subsequent removal of the
estrogen implant. However, in ORCH1E2 NAR estrogen caused
a reduction in glomerular diameter, despite the occurrence of
glomerulosclerosis. Moreover, glomeruli were smaller in non-
castrated females than in non-castrated males (Table 3). Thus, the
reduction in glomerular size observed in the ORCH1E2 NAR
should probably be regarded as an antitrophic estrogen-depen-
dent effect. This concurs with the finding in the present study, and
similar findings in Munich-Wistar rats [2], that in the absence of
marked proteinuria, ORCH rats still demonstrate larger glomer-
uli than OVX rats. The reduction of glomerular hypertrophy in
the ORCH1E2 NAR occurred in the presence of proteinuria and
glomerular injury, hence clearly dissociating primary glomerular
hypertrophy from glomerular injury in this model. Because glo-
merulosclerosis was more severe in OVX1E2 NAR than in
ORCH1E2 NAR, it is probable that in OVX1E2 NAR progres-
sive nephron loss induced a compensatory increase of glomerular
size. Finally, blood pressure was lower in ORCH1E2 NAR than
in ORCH NAR, thereby also eliminating high blood pressure as a
pathogenic factor in this model.
In summary, normotensive rats with hypertriglyceridemia, es-
trogen-treatment exacerbates the disturbance in lipid metabolism,
causing increases in both triglycerides and cholesterol. Most
probably these change contribute to the development of renal
injury by estrogen in these models. This effect of estrogen is
Table 2. Effects of estrogen on renal function and glomerular morphology in uninephrectomized orchidectomized male (ORCH), and












UprotV mg/day 4 6 0.2 209 6 25
aa 13 6 4a 19 6 11 95 6 43bc
Creatinine mmol/liter 94 6 4 85 6 10 78 6 3 82 6 8 97 6 14
G diameter mm 180 6 3 211 6 8a 188 6 1a 235 6 5aa 193 6 6bc
G macrophages 0.2 6 0.04 0.9 6 0.6a 0.3 6 0.04 0.1 6 0.02 0.6 6 0.2b
G lipid (score) 1 6 1 129 6 34aa 2 6 2 4 6 3 37 6 22c
G sclerosis (score) 1 6 0.4 107 6 21aa 3 6 1 5 6 3 61 6 33c
OVX NAR and ORCH NAR were treated with an estradiol (E2) implant for 24 weeks and untreated OVX NAR and ORCH NAR served as the
respective controls. In a subgroup of OVX 1 E2 rats, the E2 implant was removed after 12 weeks (OVX 1 E2/2E2). Proteinuria (UprotV), plasma
creatinine (creatinine), glomerular (G) diameter, macrophages (number per glomerulus) and lipid deposition (G lipid) and sclerosis (G sclerosis) were
measured at the end of the experiment.
a P , 0.05, aa P , 0.01 vs. OVX
b P , 0.05, vs. ORCH
c P , 0.05 vs. OVX 1 E2
Table 3. Plasma lipids, renal function and glomerular morphology in






CH mM 10.9 6 1.0aa 5.5 6 0.3
TG mM 4.1 6 0.3aa 1.7 6 0.3
UprotV mg/day 75 6 35 14 6 1
Creatinine mmol/liter 63 6 4 60 6 1
SBP mm Hg 150 6 4 157 6 6
G diameter mm 158 6 6a 175 6 3
G macrophages 0.8 6 0.3 0.3 6 0.0
G lipid (score) 23 6 13a 0 6 0
G sclerosis (score) 9 6 8 0 6 0
Plasma cholesterol (CH), triglycerides (TG), proteinuria (UprotV),
plasma creatinine (creatinine), systolic blood pressure (SBP) and glomer-
ular (G) diameter, macrophages (number per glomerulus) and lipid
deposition (G lipid) and sclerosis (G sclerosis) were measured 22 weeks
after uninephrectomy.
a P , 0.05, aa P , 0.01 vs. males
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unique for the hypertriglyceridemic state and can result in exces-
sively high triglyceride levels. It is unknown whether in patients
this effect could contribute to the development or progression of
renal injury. This deserves further study and should be kept in
mind when considering estrogen-replacement in post-menopausal
subjects with deranged lipoprotein metabolism.
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APPENDIX
Abbreviations used in this article are: E2, 17B-estradiol; HDL, high
density lipoprotein; IDL, intermediate density lipoprotein; LDL, low
density lipoprotein; NAR, analbuminemic rats; ORCH, orchidectomized;
OVX, ovariectomized; PBS, phosphate buffered saline; UNX, unine-
phrectomy; VLDL, very low density lipoprotein.
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